28.00GBp0.00%Mkt Cap: 42.40M $P/E: —Today
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a T…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
 We're Keeping An Eye On Sareum Holdings' (LON:SAR) Cash Burn Rate We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... | ||
Sareum Holdings PLC (STU:RYH0) Half Year 2026 Earnings Call Highlights: Advancing Pipeline ... Sareum Holdings PLC (STU:RYH0) showcases progress in drug development and strategic partnerships, despite facing setbacks and uncertainties. | ||
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate We can readily understand why investors are attracted to unprofitable companies. For example, although... | ||